Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy

Table 6 Overall response rate and disease-control rate (n = 66)

Characteristic			ORR (%)	P-value	DCR (%)	P-value
Age	<60 ≥ 60		35.3 31.6	.784	61.8 68.4	.628
Sex	Male Female		30.3 40.0	.470	69.7 55.0	.279
	Pancreas		35.7		71.4
Origin	GI		30.8	1.000	38.5	.055
	Lung		0.0		0.0
Liver metastasis	Absent Present		58.8 22.2	.009	82.4 55.6	.072
	1		33.3		66.7
	2-3		44.4		66.7
Grade				.460		.433
	Large		40.0		40.0
	Small		33.3		100.0
	24-hour urine 5-HIAA (μmol/day)	<31.4 ≥ 31.4	0.0 33.3	.455	20.0 66.7	.242
Biomarkers
	Serum NSE (nmol/l)	<1.0 ≥ 1.0	0.0 55.6	.034	28.6 77.8	.126
	IFN		23.1		53.8
Regimen	Somatostatin-analogue*		0.0	.400	0.0	.079
	Chemotherapy		39.5		71.1

ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon
*Somatostatin-analogue was given to only 2 patients.

ISSN: 1471-2407